Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CARL DANZIG

Allopathic & Osteopathic Physicians Ophthalmology

NPI
1619137320
CMS profile
209355
Location
POMPANO BEACH, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$150,110.30

150 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Page 3 of 3; records 101–150 of 150 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CARL DANZIG

NPI 1619137320 · CMS profile ID 209355

Allopathic & Osteopathic Physicians / Ophthalmology

POMPANO BEACH, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–150 of 150 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1619137320?year=2025&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CARL DANZIG, NPI 1619137320, CMS profile ID 209355. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–150 of 150 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1619137320?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). CARL DANZIG, NPI 1619137320, CMS profile ID 209355. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–150 of 150 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1619137320?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
CARL DANZIG, NPI 1619137320, CMS profile ID 209355, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–150 of 150 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1619137320?year=2025&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

150 matching records · $150,110.30 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 150 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 150.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Ocular Therapeutix, Inc. $1,000.0007/15/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1250226754 CMS
Genentech, Inc. $840.0007/02/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1211500659 CMS
Genentech, Inc. $840.0007/02/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1211500661 CMS
Ocular Therapeutix, Inc. $2,500.0006/21/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1250226750 CMS
ABBVIE INC. $59.7206/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201725704 CMS
Ocular Therapeutix, Inc. $1,833.3306/20/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1250226756 CMS
Ocular Therapeutix, Inc. $2,000.0006/19/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1250226732 CMS
Ocular Therapeutix, Inc. $242.1206/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250226820 CMS
Ocular Therapeutix, Inc. $1,000.0006/18/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1250226798 CMS
Ocular Therapeutix, Inc. $500.0006/17/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1250226742 CMS
Astellas Pharma US Inc $900.0006/12/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1238709464 CMS
Astellas Pharma US Inc $7,200.0006/07/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1238709542 CMS
Astellas Pharma US Inc $292.6006/07/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1238709726 CMS
Astellas Pharma US Inc $118.2506/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238709730 CMS
Astellas Pharma US Inc $446.0006/07/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1238709734 CMS
Astellas Pharma Global Development $2,769.0006/06/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1234125942 CMS
Ocular Therapeutix, Inc. $1,000.0005/29/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1250226734 CMS
ANI Pharmaceuticals, Inc. $22.5805/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248656528 CMS
Ocular Therapeutix, Inc. $18.1005/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250226810 CMS
Ocular Therapeutix, Inc. $1,000.0005/11/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1250226782 CMS
Ocular Therapeutix, Inc. $500.0005/10/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1250226748 CMS
Ocular Therapeutix, Inc. $500.0005/09/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1250226796 CMS
Ocular Therapeutix, Inc. $29.4305/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250226812 CMS
Genentech, Inc. $28.4905/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211500657 CMS
Regeneron Pharmaceuticals, Inc. $18.3005/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1213237059 CMS
Ocular Therapeutix, Inc. $1,000.0005/05/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1250226738 CMS
Ocular Therapeutix, Inc. $117.1805/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250226818 CMS
Genentech USA, Inc. $12.3905/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211500645 CMS
Ocular Therapeutix, Inc. $500.0004/27/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1250226740 CMS
Ocular Therapeutix, Inc. $500.0004/24/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1250226774 CMS
Ocular Therapeutix, Inc. $500.0004/24/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1250226788 CMS
Apellis Pharmaceuticals, Inc. $30.1904/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1253191026 CMS
Ocular Therapeutix, Inc. $2,000.0004/04/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1250226758 CMS
Ocular Therapeutix, Inc. $110.9204/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250226814 CMS
Ocular Therapeutix, Inc. $1,000.0004/01/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1250226736 CMS
Ocular Therapeutix, Inc. $1,000.0003/18/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1250226772 CMS
Apellis Pharmaceuticals, Inc. $25.4103/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1253191024 CMS
Ocular Therapeutix, Inc. $1,000.0003/03/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1250226790 CMS
Ocular Therapeutix, Inc. $2,500.0002/22/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1250226744 CMS
Ocular Therapeutix, Inc. $1,000.0002/07/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1250226800 CMS
Ocular Therapeutix, Inc. $3.5202/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250226806 CMS
Ocular Therapeutix, Inc. $16.0302/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250226808 CMS
ANI Pharmaceuticals, Inc. $16.0502/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248593171 CMS
ANI Pharmaceuticals, Inc. $70.3002/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248595196 CMS
Regeneron Healthcare Solutions, Inc. $120.6501/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212898745 CMS
Ocular Therapeutix, Inc. $1,500.0001/27/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1250226778 CMS
Ocular Therapeutix, Inc. $500.0001/20/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1250226762 CMS
Ocular Therapeutix, Inc. $250.0001/20/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1250226784 CMS
Samsung Bioepis Co., Ltd. $712.5001/16/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1219721999 CMS
ABBVIE INC. $142.3801/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201725702 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $45,558.55 68
PY2020 $23,858.20 16
PY2021 $23,013.05 31
PY2022 $44,646.58 59
PY2023 $60,189.00 68
PY2024 $136,401.80 97
PY2025 $150,110.30 150

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $12,259.42 5
PY2025 Principal investigator $454,878.76 200
PY2024 Recipient $11,426.05 5
PY2024 Principal investigator $540,270.42 147
PY2023 Recipient $2,329.88 4
PY2023 Principal investigator $527,421.56 174
PY2022 Principal investigator $623,708.70 89
PY2021 Recipient $9,310.75 4
PY2021 Principal investigator $606,141.71 70
PY2020 Recipient $10,996.39 6
PY2020 Principal investigator $1,198,521.25 30
PY2019 Principal investigator $862,840.66 50

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

205 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Ocular Therapeutix, Inc. $2,917.00 12/31/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250241181
Principal investigator 1 Ocular Therapeutix, Inc. $275.00 12/31/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250241183
Principal investigator 1 Ocular Therapeutix, Inc. $75.00 12/31/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250241185
Principal investigator 1 Ocular Therapeutix, Inc. $75.00 12/31/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250241187
Principal investigator 1 Ocular Therapeutix, Inc. $75.00 12/31/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250241189
Principal investigator 1 Ocular Therapeutix, Inc. $75.00 12/29/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250241179
Principal investigator 1 Ocular Therapeutix, Inc. $15,526.80 12/24/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250241175
Principal investigator 1 Ocular Therapeutix, Inc. $14,206.50 12/24/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250241177
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $9,258.00 12/22/2025 Non-covered Recipient Entity
William J. Rand MDPA
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220813671
Principal investigator 1 Ocular Therapeutix, Inc. $75.00 12/17/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250241167
Principal investigator 1 Ocular Therapeutix, Inc. $75.00 12/17/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250241169
Principal investigator 1 Ocular Therapeutix, Inc. $75.00 12/17/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250241171
Principal investigator 1 Ocular Therapeutix, Inc. $75.00 12/17/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250241173
Principal investigator 1 Ocular Therapeutix, Inc. $1,244.50 12/12/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250241157
Principal investigator 1 Ocular Therapeutix, Inc. $75.00 12/12/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250241159
Principal investigator 1 Ocular Therapeutix, Inc. $75.00 12/12/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250241161
Principal investigator 1 Ocular Therapeutix, Inc. $75.00 12/12/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250241163
Principal investigator 1 Ocular Therapeutix, Inc. $75.00 12/12/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250241165
Principal investigator 1 Ocular Therapeutix, Inc. $75.00 12/05/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250241155
Principal investigator 1 Ocular Therapeutix, Inc. $280.00 12/03/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250241152
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 12/01/2025 Non-covered Recipient Entity
Rand Eye Institute
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220652634
Principal investigator 1 Ocular Therapeutix, Inc. $275.00 12/01/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250241146
Principal investigator 1 Ocular Therapeutix, Inc. $75.00 12/01/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250241148
Principal investigator 1 Ocular Therapeutix, Inc. $4,181.40 12/01/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250241150
Principal investigator 1 Ocular Therapeutix, Inc. $75.00 11/12/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250241134
Principal investigator 1 Ocular Therapeutix, Inc. $75.00 11/12/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250241136
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $445.00 11/11/2025 Non-covered Recipient Entity
William J. Rand MDPA
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220813669
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $857.25 11/05/2025 Non-covered Recipient Entity
Rand Eye Institute
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225409712
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $135.00 11/05/2025 Non-covered Recipient Entity
Rand Eye Institute
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225409756
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 11/01/2025 Non-covered Recipient Entity
Rand Eye Institute
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220652632
Principal investigator 1 Ocular Therapeutix, Inc. $1,014.00 10/17/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250241130
Principal investigator 1 Ocular Therapeutix, Inc. $200.00 10/14/2025 Non-covered Recipient Entity
Rand Eye Institute
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250236499
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $8,875.00 10/10/2025 Non-covered Recipient Entity
William J. Rand MDPA
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220813667
Principal investigator 1 Ocular Therapeutix, Inc. $21,193.20 10/08/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250241124
Principal investigator 1 Ocular Therapeutix, Inc. $75.00 10/08/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250241126
Principal investigator 1 Ocular Therapeutix, Inc. $2,917.00 10/08/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250241128
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 10/01/2025 Non-covered Recipient Entity
Rand Eye Institute
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220652630
Principal investigator 1 Ocular Therapeutix, Inc. $314.00 09/26/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250241122
Recipient F. Hoffmann-La Roche AG $644.00 09/19/2025 Covered Recipient Physician A PHASE III STUDY TO EVALUATE FARICIMAB IN PATIENTS WITH CENTRAL RETINAL VEIN OCCLUSION No dispute reported 06/30/2026 1211535025
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $398.00 09/10/2025 Non-covered Recipient Entity
William J. Rand MDPA
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220813663
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $680.00 09/10/2025 Non-covered Recipient Entity
William J. Rand MDPA
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220813665
Principal investigator 1 Ocular Therapeutix, Inc. $3,774.06 09/10/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250241120
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $135.00 09/08/2025 Non-covered Recipient Entity
Rand Eye Institute
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225410514
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $300.00 09/08/2025 Non-covered Recipient Entity
Rand Eye Institute
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225410750
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $100.00 09/08/2025 Non-covered Recipient Entity
Rand Eye Institute
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225411210
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $97.20 09/08/2025 Non-covered Recipient Entity
Rand Eye Institute
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225411406
Principal investigator 1 Ocular Therapeutix, Inc. $496.40 09/03/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250241096
Principal investigator 1 Ocular Therapeutix, Inc. $314.40 09/03/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250241098
Principal investigator 1 Ocular Therapeutix, Inc. $314.40 09/03/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250241100
Principal investigator 1 Ocular Therapeutix, Inc. $314.40 09/03/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250241102
Principal investigator 1 Ocular Therapeutix, Inc. $314.40 09/03/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250241104
Principal investigator 1 Ocular Therapeutix, Inc. $75.00 09/03/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250241106
Principal investigator 1 Ocular Therapeutix, Inc. $125.00 09/03/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250241108
Principal investigator 1 Ocular Therapeutix, Inc. $496.40 09/03/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250241110
Principal investigator 1 Ocular Therapeutix, Inc. $75.00 09/03/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250241112
Principal investigator 1 Ocular Therapeutix, Inc. $3,640.00 09/03/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250241114
Principal investigator 1 Ocular Therapeutix, Inc. $2,840.00 09/03/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250241116
Principal investigator 1 Ocular Therapeutix, Inc. $1,434.00 09/03/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250241118
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 09/01/2025 Non-covered Recipient Entity
Rand Eye Institute
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220652628
Principal investigator 1 Ocular Therapeutix, Inc. $1,495.00 08/29/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250241092
Principal investigator 1 Ocular Therapeutix, Inc. $7,465.50 08/29/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250241094
Principal investigator 1 Ocular Therapeutix, Inc. $1,244.50 08/27/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250241090
Principal investigator 1 Ocular Therapeutix, Inc. $2,515.00 08/20/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250241088
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $22,516.00 08/18/2025 Non-covered Recipient Entity
William J. Rand MDPA
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220813661
Principal investigator 1 Ocular Therapeutix, Inc. $175.00 08/15/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250241084
Principal investigator 1 Ocular Therapeutix, Inc. $175.00 08/15/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250241086
Principal investigator 1 Ocular Therapeutix, Inc. $1,120.00 08/13/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250241082
Principal investigator 1 Ocular Therapeutix, Inc. $10,371.60 08/08/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250241080
Principal investigator 1 Ocular Therapeutix, Inc. $1,395.00 08/06/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250241060
Principal investigator 1 Ocular Therapeutix, Inc. $2,615.00 08/06/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250241062
Principal investigator 1 Ocular Therapeutix, Inc. $75.00 08/06/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250241064
Principal investigator 1 Ocular Therapeutix, Inc. $75.00 08/06/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250241066
Principal investigator 1 Ocular Therapeutix, Inc. $2,564.50 08/06/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250241068
Principal investigator 1 Ocular Therapeutix, Inc. $175.00 08/06/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250241070
Principal investigator 1 Ocular Therapeutix, Inc. $1,295.00 08/06/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250241072
Principal investigator 1 Ocular Therapeutix, Inc. $75.00 08/06/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250241074
Principal investigator 1 Ocular Therapeutix, Inc. $75.00 08/06/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250241076
Principal investigator 1 Ocular Therapeutix, Inc. $314.40 08/06/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250241078
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 08/01/2025 Non-covered Recipient Entity
Rand Eye Institute
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220652626
Recipient F. Hoffmann-La Roche AG $685.71 08/01/2025 Covered Recipient Physician A PHASE III STUDY TO EVALUATE FARICIMAB IN PATIENTS WITH CENTRAL RETINAL VEIN OCCLUSION No dispute reported 06/30/2026 1211535029
Principal investigator 1 Ocular Therapeutix, Inc. $1,634.40 08/01/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250241053
Principal investigator 1 Ocular Therapeutix, Inc. $314.40 08/01/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250241055
Principal investigator 1 Ocular Therapeutix, Inc. $1,483.90 08/01/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250241058
Principal investigator 1 Ocular Therapeutix, Inc. $3,470.00 07/30/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250241051
Principal investigator 1 Ocular Therapeutix, Inc. $6,440.00 07/25/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250241045
Principal investigator 1 Ocular Therapeutix, Inc. $16,014.60 07/25/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250241047
Principal investigator 1 Ocular Therapeutix, Inc. $3,774.06 07/25/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250241049
Principal investigator 1 Ocular Therapeutix, Inc. $2,840.00 07/23/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250241039
Principal investigator 1 Ocular Therapeutix, Inc. $314.40 07/23/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250241041
Principal investigator 1 Ocular Therapeutix, Inc. $225.00 07/23/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250241043
Principal investigator 1 Ocular Therapeutix, Inc. $75.00 07/18/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250241035
Principal investigator 1 Ocular Therapeutix, Inc. $75.00 07/18/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250241037
Principal investigator 1 Ocular Therapeutix, Inc. $425.00 07/16/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250241033
Principal investigator 1 Ocular Therapeutix, Inc. $75.00 07/11/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250241021
Principal investigator 1 Ocular Therapeutix, Inc. $75.00 07/11/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250241023
Principal investigator 1 Ocular Therapeutix, Inc. $75.00 07/11/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250241025
Principal investigator 1 Ocular Therapeutix, Inc. $75.00 07/11/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250241027
Principal investigator 1 Ocular Therapeutix, Inc. $75.00 07/11/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250241029
Principal investigator 1 Ocular Therapeutix, Inc. $75.00 07/11/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250241031
Principal investigator 1 Ocular Therapeutix, Inc. $14,931.00 07/02/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250241009
Principal investigator 1 Ocular Therapeutix, Inc. $75.00 07/02/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250241011
Principal investigator 1 Ocular Therapeutix, Inc. $75.00 07/02/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250241013
Principal investigator 1 Ocular Therapeutix, Inc. $75.00 07/02/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250241015
Principal investigator 1 Ocular Therapeutix, Inc. $75.00 07/02/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250241017
Principal investigator 1 Ocular Therapeutix, Inc. $475.00 07/02/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250241019
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 07/01/2025 Non-covered Recipient Entity
Rand Eye Institute
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220652624
Recipient Ocular Therapeutix, Inc. $9,600.00 06/30/2025 Covered Recipient Physician Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250229187
Principal investigator 1 Genentech, Inc. $68.00 06/18/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA 2
iAMD Observational Study No dispute reported 06/30/2026 1211685404
Principal investigator 1 Ocular Therapeutix, Inc. $135.00 06/18/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250241001
Recipient F. Hoffmann-La Roche AG $685.71 06/16/2025 Covered Recipient Physician Association of early macular leakage resolution with extended treatment intervals in patients with RVO: A BALATON/COMINO post hoc analysis No dispute reported 06/30/2026 1211535033
Principal investigator 1 Ocular Therapeutix, Inc. $740.00 06/13/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240997
Principal investigator 1 Ocular Therapeutix, Inc. $4,131.90 06/13/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240999
Principal investigator 1 Ocular Therapeutix, Inc. $1,797.00 06/11/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240989
Principal investigator 1 Ocular Therapeutix, Inc. $75.00 06/11/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240991
Principal investigator 1 Ocular Therapeutix, Inc. $13,757.40 06/11/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240993
Principal investigator 1 Ocular Therapeutix, Inc. $2,840.00 06/11/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240995
Principal investigator 1 Ocular Therapeutix, Inc. $2,427.00 06/06/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240987
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $13,400.00 06/02/2025 Non-covered Recipient Entity
William J. Rand MDPA
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220813659
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 06/01/2025 Non-covered Recipient Entity
Rand Eye Institute
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220652610
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $3,873.15 05/28/2025 Non-covered Recipient Entity
Rand Eye Institute
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225407746
Principal investigator 1 Ocular Therapeutix, Inc. $75.00 05/28/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240979
Principal investigator 1 Ocular Therapeutix, Inc. $75.00 05/28/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240981
Principal investigator 1 Ocular Therapeutix, Inc. $75.00 05/28/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240983
Principal investigator 1 Ocular Therapeutix, Inc. $75.00 05/28/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240985
Principal investigator 1 Boehringer Ingelheim International GmbH $34.98 05/27/2025 Non-covered Recipient Entity
Rand Eye Institute
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220652612
Principal investigator 1 Boehringer Ingelheim International GmbH $139.86 05/27/2025 Non-covered Recipient Entity
Rand Eye Institute
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220652614
Principal investigator 1 Boehringer Ingelheim International GmbH $365.00 05/27/2025 Non-covered Recipient Entity
Rand Eye Institute
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220652616
Principal investigator 1 Boehringer Ingelheim International GmbH $85.84 05/27/2025 Non-covered Recipient Entity
Rand Eye Institute
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220652618
Principal investigator 1 Boehringer Ingelheim International GmbH $9.00 05/27/2025 Non-covered Recipient Entity
Rand Eye Institute
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220652620
Principal investigator 1 Boehringer Ingelheim International GmbH $1.83 05/27/2025 Non-covered Recipient Entity
Rand Eye Institute
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220652622
Principal investigator 1 Ocular Therapeutix, Inc. $49,127.40 05/16/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240975
Principal investigator 1 Ocular Therapeutix, Inc. $1,634.00 05/16/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240977
Principal investigator 1 Ocular Therapeutix, Inc. $31,609.80 05/14/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240973
Principal investigator 1 Novartis Pharmaceuticals Corporation $3,000.00 05/02/2025 Non-covered Recipient Entity
RAND EYE INSTITUTE, INC
ORACLE: A Long-term Follow-up Study to Evaluate the Safety of GT005 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration Treated in a Gyroscope-sponsored Antecedent Study No dispute reported 06/30/2026 1190308084
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 05/01/2025 Non-covered Recipient Entity
Rand Eye Institute
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220652608
Principal investigator 1 Genentech, Inc. $14,522.00 05/01/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA 2
iAMD Observational Study No dispute reported 06/30/2026 1211685402
Principal investigator 1 Genentech, Inc. $585.00 05/01/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA 2
iAMD Observational Study No dispute reported 06/30/2026 1211685406
Principal investigator 1 Genentech, Inc. $159.00 05/01/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA 2
iAMD Observational Study No dispute reported 06/30/2026 1211685408
Principal investigator 1 Genentech, Inc. $273.00 05/01/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA 2
iAMD Observational Study No dispute reported 06/30/2026 1211685410
Principal investigator 1 Genentech, Inc. $65.00 05/01/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA 2
iAMD Observational Study No dispute reported 06/30/2026 1211685412
Principal investigator 1 Genentech, Inc. $68.00 05/01/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA 2
iAMD Observational Study No dispute reported 06/30/2026 1211685414
Principal investigator 1 Ocular Therapeutix, Inc. $314.00 04/16/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240971
Recipient F. Hoffmann-La Roche AG $644.00 04/14/2025 Covered Recipient Physician A PHASE III STUDY TO EVALUATE FARICIMAB IN PATIENTS WITH CENTRAL RETINAL VEIN OCCLUSION No dispute reported 06/30/2026 1211535021
Principal investigator 1 Ocular Therapeutix, Inc. $75.00 04/09/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240967
Principal investigator 1 Ocular Therapeutix, Inc. $75.00 04/09/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240969
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $97.20 04/02/2025 Non-covered Recipient Entity
Rand Eye Institute
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225404850
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $100.00 04/02/2025 Non-covered Recipient Entity
Rand Eye Institute
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225405554
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $135.00 04/02/2025 Non-covered Recipient Entity
Rand Eye Institute
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225406966
Principal investigator 1 Ocular Therapeutix, Inc. $75.00 04/02/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240963
Principal investigator 1 Ocular Therapeutix, Inc. $75.00 04/02/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240965
Principal investigator 1 Boehringer Ingelheim International GmbH $43.00 04/01/2025 Non-covered Recipient Entity
Rand Eye Institute
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220652600
Principal investigator 1 Boehringer Ingelheim International GmbH $23.75 04/01/2025 Non-covered Recipient Entity
Rand Eye Institute
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220652602
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 04/01/2025 Non-covered Recipient Entity
Rand Eye Institute
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220652604
Principal investigator 1 Boehringer Ingelheim International GmbH $24.94 04/01/2025 Non-covered Recipient Entity
Rand Eye Institute
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220652606
Principal investigator 1 Boehringer Ingelheim International GmbH $34.98 03/25/2025 Non-covered Recipient Entity
Rand Eye Institute
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220652586
Principal investigator 1 Boehringer Ingelheim International GmbH $139.86 03/25/2025 Non-covered Recipient Entity
Rand Eye Institute
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220652588
Principal investigator 1 Boehringer Ingelheim International GmbH $365.00 03/25/2025 Non-covered Recipient Entity
Rand Eye Institute
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220652590
Principal investigator 1 Boehringer Ingelheim International GmbH $85.84 03/25/2025 Non-covered Recipient Entity
Rand Eye Institute
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220652592
Principal investigator 1 Boehringer Ingelheim International GmbH $7.44 03/25/2025 Non-covered Recipient Entity
Rand Eye Institute
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220652594
Principal investigator 1 Boehringer Ingelheim International GmbH $9.00 03/25/2025 Non-covered Recipient Entity
Rand Eye Institute
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220652596
Principal investigator 1 Boehringer Ingelheim International GmbH $1.83 03/25/2025 Non-covered Recipient Entity
Rand Eye Institute
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220652598
Principal investigator 1 Boehringer Ingelheim International GmbH $69.96 03/25/2025 Non-covered Recipient Entity
Rand Eye Institute
Phase II PAFRa in GA No dispute reported 06/30/2026 1220652636
Principal investigator 1 Boehringer Ingelheim International GmbH $319.68 03/25/2025 Non-covered Recipient Entity
Rand Eye Institute
Phase II PAFRa in GA No dispute reported 06/30/2026 1220652638
Principal investigator 1 Boehringer Ingelheim International GmbH $328.50 03/25/2025 Non-covered Recipient Entity
Rand Eye Institute
Phase II PAFRa in GA No dispute reported 06/30/2026 1220652640
Principal investigator 1 Boehringer Ingelheim International GmbH $7.00 03/25/2025 Non-covered Recipient Entity
Rand Eye Institute
Phase II PAFRa in GA No dispute reported 06/30/2026 1220652642
Principal investigator 1 Ocular Therapeutix, Inc. $75.00 03/14/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250241007
Principal investigator 1 Ocular Therapeutix, Inc. $275.00 03/12/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250241003
Principal investigator 1 Ocular Therapeutix, Inc. $9,651.60 03/12/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250241005
Principal investigator 1 Genentech, Inc. $130.00 03/07/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA 2
iAMD Observational Study No dispute reported 06/30/2026 1211685370
Principal investigator 1 Genentech, Inc. $950.00 03/07/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA 2
iAMD Observational Study No dispute reported 06/30/2026 1211685372
Principal investigator 1 Genentech, Inc. $68.00 03/07/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA 2
iAMD Observational Study No dispute reported 06/30/2026 1211685374
Principal investigator 1 Genentech, Inc. $68.00 03/07/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA 2
iAMD Observational Study No dispute reported 06/30/2026 1211685378
Principal investigator 1 Genentech, Inc. $68.00 03/07/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA 2
iAMD Observational Study No dispute reported 06/30/2026 1211685386
Principal investigator 1 Genentech, Inc. $68.00 03/07/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA 2
iAMD Observational Study No dispute reported 06/30/2026 1211685388
Principal investigator 1 Genentech, Inc. $68.00 03/07/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA 2
iAMD Observational Study No dispute reported 06/30/2026 1211685392
Principal investigator 1 Genentech, Inc. $68.00 03/07/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA 2
iAMD Observational Study No dispute reported 06/30/2026 1211685394
Principal investigator 1 Genentech, Inc. $68.00 03/07/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA 2
iAMD Observational Study No dispute reported 06/30/2026 1211685396
Principal investigator 1 Genentech, Inc. $1,306.00 03/07/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA 2
iAMD Observational Study No dispute reported 06/30/2026 1211685398
Principal investigator 1 Genentech, Inc. $65.00 03/07/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA 2
iAMD Observational Study No dispute reported 06/30/2026 1211685400
Principal investigator 1 Ocular Therapeutix, Inc. $75.00 02/28/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240961
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $3,350.70 02/27/2025 Non-covered Recipient Entity
Rand Eye Institute
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225406380
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $3,873.15 02/27/2025 Non-covered Recipient Entity
Rand Eye Institute
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225406382
Principal investigator 1 Alexion Pharmaceuticals, Inc. $10,475.45 02/26/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
A Phase 2, Double Masked, Placebo Controlled, Dose Range Finding Study of Danicopan (ALXN2040) in Patients with Geographic Atrophy (GA) Secondary to Age Related Macular Degeneration (AMD) No dispute reported 06/30/2026 1185555818
Principal investigator 1 Genentech, Inc. $4,170.00 02/26/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA 2
iAMD Observational Study No dispute reported 06/30/2026 1211685380
Principal investigator 1 Ocular Therapeutix, Inc. $275.00 02/19/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240955
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $239.05 02/12/2025 Non-covered Recipient Entity
Rand Eye Institute
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220794335
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,500.00 02/07/2025 Non-covered Recipient Entity
RAND EYE INSTITUTION
A Phase 3 Randomized, Double-Masked, Active-Controlled Study of the Efficacy and Safety of 8 MG Aflibercept in Participants with Macular Edema Following Retinal Vein Occlusion No dispute reported 06/30/2026 1184152840
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,800.00 02/07/2025 Non-covered Recipient Entity
RAND EYE INSTITUTION
A Phase 3 Randomized, Double-Masked, Active-Controlled Study of the Efficacy and Safety of 8 MG Aflibercept in Participants with Macular Edema Following Retinal Vein Occlusion No dispute reported 06/30/2026 1184152842
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,838.00 02/07/2025 Non-covered Recipient Entity
RAND EYE INSTITUTION
A Phase 3 Randomized, Double-Masked, Active-Controlled Study of the Efficacy and Safety of 8 MG Aflibercept in Participants with Macular Edema Following Retinal Vein Occlusion No dispute reported 06/30/2026 1184152844
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,500.00 02/07/2025 Non-covered Recipient Entity
RAND EYE INSTITUTION
A Phase 3 Randomized, Double-Masked, Active-Controlled Study of the Efficacy and Safety of 8 MG Aflibercept in Participants with Macular Edema Following Retinal Vein Occlusion No dispute reported 06/30/2026 1184152846
Principal investigator 1 Genentech, Inc. $5,828.00 02/05/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA 2
iAMD Observational Study No dispute reported 06/30/2026 1211685382
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $3,350.70 01/30/2025 Non-covered Recipient Entity
Rand Eye Institute
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225404060
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $3,350.70 01/30/2025 Non-covered Recipient Entity
Rand Eye Institute
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225404469
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $3,350.70 01/30/2025 Non-covered Recipient Entity
Rand Eye Institute
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225406378
Principal investigator 1 Ocular Therapeutix, Inc. $75.00 01/24/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240949
Principal investigator 1 Ocular Therapeutix, Inc. $75.00 01/24/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240951
Principal investigator 1 Ocular Therapeutix, Inc. $1,444.50 01/24/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240953
Principal investigator 1 Ocular Therapeutix, Inc. $1,395.00 01/24/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240957
Principal investigator 1 Ocular Therapeutix, Inc. $24,885.00 01/24/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240959
Principal investigator 1 Genentech, Inc. $68.00 01/22/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA 2
iAMD Observational Study No dispute reported 06/30/2026 1211685376
Principal investigator 1 Genentech, Inc. $68.00 01/22/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA 2
iAMD Observational Study No dispute reported 06/30/2026 1211685384
Principal investigator 1 Genentech, Inc. $68.00 01/22/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA 2
iAMD Observational Study No dispute reported 06/30/2026 1211685390
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $135.00 01/15/2025 Non-covered Recipient Entity
Rand Eye Institute
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225405924
Principal investigator 1 Ocular Therapeutix, Inc. $275.00 01/13/2025 Non-covered Recipient Entity
WILLIAM J RAND MD PA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240947
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $135.00 01/09/2025 Non-covered Recipient Entity
Rand Eye Institute
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225405944